Molten Ventures leads a €31 million Series C investment in Deciphex to enhance AI-powered digital pathology and address critical healthcare diagnostic challenges.

Target Information

Deciphex is a pioneering company focused on AI-powered digital pathology solutions. By leveraging advanced technology, the company aims to bridge the gap in pathology diagnostics, addressing the growing demand for high-quality pathology services. The recent €31 million Series C funding round, led by Molten Ventures, reinforces Deciphex's commitment to enhancing healthcare diagnostics globally.

The company’s innovative platform empowers pathologists by improving their workflow efficiency and diagnostic accuracy. With more than 70% of healthcare decisions relying on pathology investigations, Deciphex's AI tools allow pathologists to work up to 40% faster, mitigating the backlog issues commonly faced in healthcare systems worldwide.

Industry Overview

The healthcare industry, particularly pathology, is facing unprecedented challenges, with a critical shortage of pathologists juxtaposed against rising patient demands. As healthcare systems worldwide grapple wi

View Source

Similar Deals

Haemonetics Corporation Vivasure Medical Limited

2025

Other Medical Devices & Implants Ireland
UFP Technologies AQF Medical

2022

Other Medical Equipment, Supplies & Distribution (NEC) Ireland
Advanced CareWorks

2021

Other Healthcare Facilities & Services (NEC) Ireland
Diamond Pharma Services PharmaCentral

Other Pharmaceuticals (NEC) Ireland
Specac, Ltd Amax Precision Ltd

2026

Other Advanced Medical Equipment & Technology (NEC) Singapore

Molten Ventures

invested in

Deciphex

in

in a Other deal

Disclosed details

Transaction Size: $31M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert